Reports > Life Sciences > Artificial Heartlung Machine Market Report
Artificial Heartlung Machine Market Size, Share, Industry Trends and Forecast to 2033
This report provides an in-depth analysis of the Artificial Heartlung Machine market, highlighting insights on market size, growth forecasts, and industry trends for the period 2023 to 2033.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.70 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $11.65 Billion |
| Top Companies | Medtronic, Abbott Laboratories, Terumo Corporation, Getinge AB, Sorin Group |
| Last Modified Date | 15 Nov 2024 |
Artificial Heartlung Machine Market Report (2023 - 2033)
Artificial Heartlung Machine Market Overview
What is the Market Size & CAGR of Artificial Heartlung Machine market in 2023?
Artificial Heartlung Machine Industry Analysis
Artificial Heartlung Machine Market Segmentation and Scope
Request a custom research report for industry.
Artificial Heartlung Machine Market Analysis Report by Region
Europe Artificial Heartlung Machine Market Report:
The European market is projected to grow from $1.62 billion in 2023 to $3.31 billion by 2033. Factors driving this market include aging populations, advancements in surgical procedures, and competitive healthcare frameworks that foster innovation and accessibility of heartlung machines.Asia Pacific Artificial Heartlung Machine Market Report:
In 2023, the Asia Pacific market for Artificial Heartlung Machines is valued at $1.09 billion, projected to grow to $2.23 billion by 2033. This growth is attributed to rising healthcare expenditures, increasing prevalence of cardiovascular diseases, and a growing population, leading to heightened demand for advanced healthcare solutions.North America Artificial Heartlung Machine Market Report:
North America leads the market with a valuation of $1.97 billion in 2023, anticipated to expand to $4.03 billion by 2033. High healthcare spending, technological advancements, and a strong presence of key market players contribute to this rapid growth. Furthermore, an increase in the number of surgeries performed using heartlung machines underpins this promising outlook.South America Artificial Heartlung Machine Market Report:
The South American market, valued at $0.32 billion in 2023, is expected to reach $0.65 billion by 2033. Factors driving this growth include improving healthcare infrastructure, increased demand for medical technologies, and rising awareness of treatment options available for heart and lung diseases.Middle East & Africa Artificial Heartlung Machine Market Report:
Valued at $0.70 billion in 2023, the Middle East and Africa market is expected to rise to $1.43 billion by 2033. Factors such as increased healthcare investments, an uptick in surgical operations, and the introduction of advanced heartlung machines in hospitals are contributing to this growth trajectory.Request a custom research report for industry.
Artificial Heartlung Machine Market Analysis By Product
Global Artificial Heart-Lung Machine Market, By Product Market Analysis (2023 - 2033)
In 2023, the Invasive Devices segment dominates the market with a size of $3.45 billion and retains a share of 60.5%. This dominance is attributed to the necessity of invasive procedures in critical care scenarios. The Non-Invasive Devices segment, valued at $1.57 billion (27.62% share), and Consumables at $0.68 billion (11.88% share) are also significant contributors, representing their growing importance in patient care and operational efficiency.
Artificial Heartlung Machine Market Analysis By Application
Global Artificial Heart-Lung Machine Market, By Application Market Analysis (2023 - 2033)
The market by application includes key segments such as Cardiac Surgery, which dominates with a size of $2.45 billion (42.97% share) in 2023, followed by Respiratory Failure and Heart Transplantation, valued at $1.27 billion (22.25%) and $0.75 billion (13.1%), respectively. The growth in these applications is driven by advancements in surgical techniques and a growing number of patients requiring heart and lung interventions.
Artificial Heartlung Machine Market Analysis By End User
Global Artificial Heart-Lung Machine Market, By End-User Market Analysis (2023 - 2033)
Hospitals represent the largest segment by end-user, valued at $3.29 billion (57.76% share) in 2023, emphasizing their critical role in healthcare. Ambulatory Surgery Centers and Urgent Care Centers also contribute significantly, valued at $1.40 billion (24.61%) and $0.55 billion (9.58%), respectively, driven by the increasing prevalence of outpatient surgeries and urgent medical needs.
Artificial Heartlung Machine Market Analysis By Region
Global Artificial Heart-Lung Machine Market, By Region Market Analysis (2023 - 2033)
Regional analysis underscores North America's leadership in market size and growth potential. Europe follows closely with advancements in healthcare infrastructure and patient care. The Asia-Pacific region exhibits rapid growth due to rising healthcare access, while South America and the Middle East & Africa are poised for incremental expansion fueled by healthcare improvements and increased investments.
Artificial Heartlung Machine Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Artificial Heartlung Machine Industry
Medtronic:
A leading global supplier of healthcare solutions, known for innovations in cardiac devices including heartlung machines and related technology.Abbott Laboratories:
A prominent healthcare manufacturer with a focus on cardiovascular devices, contributing significantly to the development of advanced heartlung support systems.Terumo Corporation:
A diversified medical device manufacturer that focuses on innovations in heart-lung machines and cardiopulmonary support technologies.Getinge AB:
A global leader in providing advanced solutions for healthcare, particularly in critical care and surgical applications involving artificial heart and lung machines.Sorin Group:
Specialized in cardiac surgery products, including blood management devices and heartlung machines that enhance surgical procedures and patient outcomes.We're grateful to work with incredible clients.
